In this COVID-19 clinical update, Daniel Griffin summarizes current status of vaccination in the US, discusses a study on convalescent sera from Argentina, use of remdesivir in patients with kidney disease, and provides further considerations on the use of Ct values in patient management.
Hosts: Daniel Griffin and Vincent Racaniello
Click arrow to play
Download TWiV 704 (19 MB .mp3, 32 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Argentine study on plasma therapy (NEJM) 9:52
- Ct values and clinical outcome (Open Forum Inf Dis) 17:27
- Bamlanivimab fact sheet (FDA pdf) 12:08
- Cognitive defects in recovered COVID-19 patients (medRxiv) 22:16
- Letters read on TWiV 704 24:03
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Do you have a reference for the 8 month immunity stated in the podcast?
Dr. Griffin, I’m and avid listener from Windsor Ontario Canada. I have a good friend who is in hospital with COVID 19. He was intubated a few days ago after a week of ICU treatment including high flow O2 most of that time. Also has pneumonia. His hospital physicians indicate that his situation is getting worse and there is no additional treatment they can recommend for him other than wait. Are you open to being contacted for a client consultation by his physicians? Your expertise would be greatly valued at this highly critical time.